Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: A retrospective risk-factor analysis

Bone Marrow Transplantation

Volumn 47, Issue 8, 2012, Pages 1099-1104

  Wang, Y ^a   Liu, D H ^a   Xu, L P ^a   Liu, K Y ^a   Chen, H ^a   Zhang, X H ^a   Chen, Y H ^a   Han, W ^a   Wang, F R ^a   Wang, J Z ^a   Yan, C H ^a   Huang, X J ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

donor lymphocyte infusion; HLA mismatched; relapse

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ADVANCED CANCER; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CELL THERAPY; CHILD; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT; FEMALE; GENDER; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL INFUSION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SURVIVAL RATE; T CELL REPLETE HEMATOPOIETIC STEM CELL TRANSPLANTATION;

ACUTE DISEASE; ADOLESCENT; ADULT; CHILD; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; NEOPLASM STAGING; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84864879416     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.213     Document Type: Article

References (25)

1. Sierra J, Storer B, Hansen JA, Martin PJ, Petersdorf EW, Woolfrey A et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000; 26: 397-404. (Pubitemid 30649555)
2. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotypemismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447-3454.
3. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Treatment of acute leukaemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009; 15: 257-265.
4. Huang XJ, Guo NL, Ren HY, Zhang Y, Gao Z, Lu D. An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation. Chinese Med Journal 2003; 116: 736-741. (Pubitemid 36701860)
5. Huang XJ, Wang Y, Liu DH, Liu KY, Xu LP, Chen H et al. Administration of short-term immunosuppressive agents after GPBPCI reduces the incidence of GPBPCI associated acute GVHD without influencing the GVL effect. Bone Marrow Transplant 2009; 44: 309-316.
6. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Modified donor lymphocyte infusion after HLA-mismatched/haplo-identical T-cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia. J Clin Immunol 2008; 28: 276-283.
7. Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Han W et al. Superior graft-versus-leukemia effect associated with transplantation of haplo-identical compared with HLAidentical sibling donor grafts for high risk acute leukemia: a historical comparison. Biol Blood Marrow Transplant 2011; 17: 821-830.
8. Michallet M, Thomas X, Vernant JP, Kuentz M, Socié G, Espérou-Bourdeau H et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 2000; 26: 1157-1163.
9. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Haplo-identical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38: 291-297. (Pubitemid 44203779)
10. Wang Y, Xu LP, Liu KY, Liu DH, Wang J, Chen H et al. Low-dose methotrexate combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute graft-versus-host disease-safety and feasibility. Bone Marrow Transplant 2011; 46: 892-898.
11. Flower ME, Kansu E, Sullivan KM. Pathophysiology and treatment of graft-versushost disase. Hematol Oncol Clin North Am 1999; 13: 1091-1112.
12. Keith MS. Graft-vs-Host Disease. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas0 Hematopoietic Cell Transplantation. Blackwell Publishing Ltd: Oxford, UK, 2004. p. 635-664.
13. Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 2010; 45: 1388-1395.
14. Doney K, Hägglund H, Leisenring W, Chauncey T, Appelbaum FR, Storb R. Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2003; 9: 472-481. (Pubitemid 38351805)
15. Singhal S, Powles R, Henslee-Downey PJ, Chiang KY, Treleaven J, Godder K et al. Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia. Bone Marrow Transplant 2002; 29: 291-295. (Pubitemid 34229033)
16. Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C et al. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Haematologica 2002; 87: 52-58. (Pubitemid 34101113)
17. Robak T, Wrzesien-Kus A. The search for optimal treatment in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma 2002; 43: 281-291. (Pubitemid 34211003)
18. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204. (Pubitemid 26086858)
19. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haplo- identical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007; 92: 414-417. (Pubitemid 350143554)
20. Huang XJ, Wang Y, Liu DH, Liu KY, Xu LP, Chen H et al. Modified donor lymphocyte infusion (GPBPCI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia-feasibility and safety study. J Clin Immunol 2008; 28: 390-397.
21. Huang XJ, Liu DH, Xu LP, Liu KY, Chen H, Han W et al. Prophylactic infusion of donor granulocyte colony stimulating factor mobilized peripheral blood progenitor cells after allogeneic hematological stem cell transplantation in patients with high-risk leukemia. Leukemia 2006; 20: 365-368. (Pubitemid 43148683)
22. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092-1099. (Pubitemid 44154650)
23. Huang XJ, Chang YJ, Zhao XY. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions[J]. Transplant Immunol 2007; 17: 193-197.
24. Huang XJ, Chang YJ, Zhao XY. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004; 89: 1517-1524. (Pubitemid 39643521)
25. Chen SH, Li X, Huang XJ. Effect of recombinant granulocyte colony-stimulating factor on T-lymphocyte function and the mechanism of this effect. Int J Hematol 2004; 79: 178-184. (Pubitemid 38281820)